Selective Chk1 inhibitors differentially sensitize p53‐deficient cancer cells to cancer therapeutics

@article{Chen2006SelectiveCI,
  title={Selective Chk1 inhibitors differentially sensitize p53‐deficient cancer cells to cancer therapeutics},
  author={Zehan Chen and Zhan Xiao and Wen-zhen Gu and John Xue and Mai H. Bui and Peter J. Kovar and Gaoquan Li and Gary X. Wang and Zhi-Fu Tao and Yunsong Tong and Nan-horng Lin and Hing Lueng Sham and Jean Y. J. Wang and Thomas Joseph Sowin and Saul H. Rosenberg and Haiying Zhang},
  journal={International Journal of Cancer},
  year={2006},
  volume={119}
}
The majority of cancer therapeutics induces DNA damage to kill cells. Normal proliferating cells undergo cell cycle arrest in response to DNA damage, thus allowing DNA repair to protect the genome. DNA damage induced cell cycle arrest depends on an evolutionarily conserved signal transduction network in which the Chk1 kinase plays a critical role. In mammalian cells, the p53 and RB pathways further augment the cell cycle arrest response to prevent catastrophic cell death. Given the fact that… 
Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents
TLDR
It is shown that CHK1 is required to maintain genome integrity and cell viability, and that p53-proficient cells are no less sensitive to CHK 1 inhibition in the presence of DNA damage, and inhibitingCHK1 does not appear to be a promising approach for potentiation of cancer chemotherapy.
FU resistance abrogates the amplified cytotoxic effects induced by inhibiting checkpoint kinase 1 in p 53 ‐ mutated colon cancer cells
TLDR
Results indicate that 5-fu-resistance abrogated the anticancer effect amplified by Chk1 inhibition, even in p53‐deficient cancer cells, and the development of cancer‐specific therapies is urgently required.
Inhibition of Chk1 Kills Tetraploid Tumor Cells through a p53-Dependent Pathway
TLDR
It is demonstrated that, in tetraploid tumor cells, the inhibition of Chk1 sequentially triggers aberrant mitosis, p53 activation and Puma/BBC3-dependent mitochondrial apoptosis.
BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitors
TLDR
The silencing of BRCA1 or CDK12 sensitized tumor cells to CHK1 inhibitors in vitro and in vivo induced excessive amounts of DNA damage, resulting in an inability to complete the S-phase, and is suggested as a strategy for targeting BRCa1- orCDK12-deficient tumors.
The Chk1 inhibitor AZD7762 sensitises p53 mutant breast cancer cells to radiation in vitro and in vivo.
TLDR
It is demonstrated for the first time, that AZD7762 not only promotes radiation-induced apoptosis and mitotic catastrophe of p53 mutant T47D breast cancer cells in vitro, but also delays their xenograft growth in response to radiation in vivo.
5‑FU resistance abrogates the amplified cytotoxic effects induced by inhibiting checkpoint kinase 1 in p53‑mutated colon cancer cells.
TLDR
It is found that 5‑FU‑resistance abrogated the anticancer effect amplified by Chk1 inhibition, even in p53‑deficient colorectal cancer cells.
Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes
TLDR
It is proposed that promising combinations of DNA-damaging anticancer treatments with DDR-pathway inhibition would be further enhanced by activating downstream apoptotic pathways, ensuring that actual cell death is the preferred outcome of cancer treatment instead of other responses, including reversible cell cycle arrest, autophagy or senescence.
DNA damage response and prostate cancer: defects, regulation and therapeutic implications
TLDR
Specific DDR defects in prostate cancer that occur during disease progression are discussed, to summarize recent advances in understanding the regulation of DDR, and to present potential therapeutic opportunities through combinational targeting of the intact components of DDR signaling pathways.
...
...

References

SHOWING 1-10 OF 24 REFERENCES
Human Chk1 expression is dispensable for somatic cell death and critical for sustaining G2 DNA damage checkpoint.
TLDR
Chk1 small interfering RNA (siRNA) effectively eliminates Chk1 protein expression without altering the cell cycle profile or inducing apoptosis in various human cancer cell lines under normal conditions and enhances the growth inhibition conferred by DNA-damaging agents.
An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage.
TLDR
Human Chk1 is a recently identified homologue of the Schizosaccharomyces pombe checkpoint kinase gene, which is required for G2 arrest in response to DNA damage, and a potent and selective indolocarbazole inhibitor of Chk 1 kinase activity is identified and used to assess cell cycle checkpoint responses.
UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.
TLDR
UCN-01 is a potent abrogator of G2 checkpoint control in cancer cells with disrupted p53 function and might be capable of enhancing the effectiveness of DNA-damaging agents in the treatment of tumors with cells lacking normal p53function.
Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells
TLDR
It is shown here using biochemical and physiological assays that p53 is dispensable for a DNA damage checkpoint activated in the G2 phase of the cell cycle, validating the hypothesis of targeting Chk1 in rational drug design and development for anti-cancer therapies.
Chk1‐deficient tumour cells are viable but exhibit multiple checkpoint and survival defects
TLDR
Chk1 is dispensable for normal cell division in somatic DT40 cells but is essential for DNA damage‐induced G2/M arrest and a subset of replication checkpoint responses, which promote tumour cell survival after perturbations of DNA structure or metabolism.
Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint.
TLDR
It is shown that in human cells, Chk1 is phosphorylated on serine 345 (S345) in response to UV, IR, and hydroxyurea (HU).
Targeting the checkpoint kinases: chemosensitization versus chemoprotection
An important part of the cellular response to DNA damage is checkpoint activation — checkpoint kinases CHK1 and CHK2 phosphorylate key proteins to elicit cell-cycle blocks. Inhibiting these kinases
Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25.
TLDR
Results suggest a model whereby in response to DNA damage, Chk1 phosphorylates and inhibits Cdc25C, thus preventing activation of the Cdc2-cyclin B complex and mitotic entry.
...
...